ADMA - ADMA Biologics gets FDA approval for Plasma Collection Facility in Tennessee

ADMA Biologics ([[ADMA]] +12.3%) announced the FDA approval for its ADMA BioCenters plasma collection facility located in Knoxville, Tennessee.Having started operations in Q3 2020, the plasma collection center is now licensed to collect human source plasma for further manufacturing in the U.S, the company said.“With the Knoxville approval, we remain comfortably on track to achieve our goal of building out up to 10 plasma collection centers by 2024,” commented Adam Grossman, the Chief Executive Officer of ADMA.The company expects regulatory approval for another plasma collection facility located in Maryville, Tennessee in 2H 2020, and on track to file Biologics License Applications for two more facilities, the CEO added further.In May 2020, ADMA announced that its subsidiary ADMA BioCenters Georgia launched the collection of convalescent plasma from people who had COVID-19.

For further details see:

ADMA Biologics gets FDA approval for Plasma Collection Facility in Tennessee